Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CSL
Biotech
CSL pays $355M to co-develop Alentis’ ph. 2-stage fibrosis drug
Australia’s CSL is paying $355 million upfront for the rights to Alentis Therapeutics’ phase 2-stage fibrosis drug.
James Waldron
Oct 5, 2026 4:14am
Lilly pays CSL $100M for IL-6 drug that flunked transplant study
Feb 18, 2026 5:07am
Sanofi's stunning CEO switch—Chutes & Ladders
Feb 13, 2026 8:30am
CSL inks $328M Memo deal for option on antibody engineering tech
Feb 9, 2026 2:00am
CSL pays $117M for option on phase 3 blood clotting specialist
Sep 16, 2025 4:31am
CSL to lose up to 15% of staff, cut R&D costs, spin out vaccines
Aug 19, 2025 7:06am
